Ipilimumab

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 6615 publications

Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.

Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.

Journal: Health technology assessment (Winchester, England)

Published: January 20, 2026

Sex differences in thyroid dysfunction onset timing induced by immune checkpoint inhibitors: JADER disproportionality analysis.

Sex differences in thyroid dysfunction onset timing induced by immune checkpoint inhibitors: JADER disproportionality analysis.

Journal: Expert opinion on drug safety

Published: January 19, 2026

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations.

Selecting first-line immunotherapy in advanced melanoma: Current evidence on efficacy across diverse patient populations.

Journal: EJC skin cancer

Published: January 19, 2026

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 07, 2026

First-line immunotherapy-based regimens for metastatic non-small cell lung cancer: A network meta-analysis of landmark trials.

First-line immunotherapy-based regimens for metastatic non-small cell lung cancer: A network meta-analysis of landmark trials.

Journal: Tuberkuloz ve toraks

Published: January 05, 2026

A Case of Renal Cell Carcinoma with Small Bowel Metastasis Accompanied by Invagination

A Case of Renal Cell Carcinoma with Small Bowel Metastasis Accompanied by Invagination

Journal: Hinyokika kiyo. Acta urologica Japonica

Published: January 04, 2026

Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.

Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: December 27, 2025

Primary Malignant Melanoma of the Esophagus Treated with Nivolumab and Ipilimumab Post-Esophagectomy-A Case Report

Primary Malignant Melanoma of the Esophagus Treated with Nivolumab and Ipilimumab Post-Esophagectomy-A Case Report

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: December 24, 2025

Severe bilateral chorioretinopathy associated with ipilimumab in a patient with metastatic melanoma.

Severe bilateral chorioretinopathy associated with ipilimumab in a patient with metastatic melanoma.

Journal: GMS ophthalmology cases

Published: December 22, 2025

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.

ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.

Journal: Journal for immunotherapy of cancer

Published: December 17, 2025

Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials.

Dual checkpoint inhibitor therapy versus dual targeted therapy of untreated metastatic BRAF-mutant melanoma: a systematic review of randomised controlled trials.

Journal: BMJ open

Published: December 17, 2025

Tumoral Melanosis: A Benign Mimicker of Malignant Disease.

Tumoral Melanosis: A Benign Mimicker of Malignant Disease.

Journal: Cureus

Published: December 16, 2025

Showing 1-12 of 6,615

Last Updated: 02/24/2026